PPARG and pulmonary arterial hypertension: Moreover, pre-clinical studies have shown that the PPARγ ligands rosiglitazone, pioglitazone and troglitazone have some protective effects in the chronic hypoxia and monocrotaline models of pulmonary arterial hypertension in rats [12], [13], [14] with significant reductions in pulmonary vascular remodelling in both these models.